Earnings release · BIIB
Biogen Reports Third Quarter 2026 Results
Biogen Inc. · Filed · SEC Form 8-K, Item 2.02
Revenue
$2.8 billion
+11% vs a year ago
EPS (adjusted)
$2.62
not detected
Guidance
loweredoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete.
Please read the original before relying on any figure. Not investment advice.
Why it matters
Revenue climbed 11% year on year to $2.8 billion, and EPS was $2.62. The company cut its guidance, which is usually read as management's view of coming periods weakening.
Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.
What the company states
Revenue
$2.8 billion +11% vs a year ago
…Third quarter 2026 total revenue of $2.8 billion increased 11% year-over-year; Growth Portfolio1 revenue of $1.26 bil…
EPS (adjusted)
$2.62
…ven primarily by transaction-related charges; Non-GAAP diluted EPS of $2.62, reflecting $284 million of acquired IPR&D, upfront and milestone exp…
Guidance
Guidance lowered
…Biogen is raising the lower end of the reported full year 2026 Non-GAAP diluted EPS guidance range to reflect ongoing business strength and Apellis dilution favorability.…
Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.